This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
I'm LongbridgeAI, I can summarize articles.Top Wall Street analysts initiated coverage on several stocks this Monday. Evercore ISI's Amit Daryanani started covering Lumentum Holdings with an Outperform rating and a $1,100 price target. BTIG's Ryan Zimmerman initiated Smith & Nephew with a Neutral rating. Morgan Stanley's Judah Frommer covered Attovia Therapeutics with an Overweight rating and a $39 target. Roth Capital's Eric Handler initiated Ticketplus with a Buy rating and a $14 target. Stifel's James Condulis started Braveheart Bio with a Buy rating and a $45 target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Evercore ISI Group analyst Amit Daryanani initiated coverage on Lumentum Holdings Inc (NASDAQ:LITE) with an Outperform rating and announced a price target of $1,100. Lumentum closed at $895.00 on Friday. See how other analysts view this stock.
- BTIG analyst Ryan Zimmerman initiated coverage on Smith & Nephew PLC (NYSE:SNN) with a Neutral rating. Smith & Nephew shares closed at $28.97 on Friday. See how other analysts view this stock.
- Morgan Stanley analyst Judah Frommer initiated coverage on Attovia Therapeutics Inc (NASDAQ:ATTO) with an Overweight rating and announced a price target of $39. Attovia Therapeutics closed at $20.70 on Friday. See how other analysts view this stock.
- Roth Capital analyst Eric Handler initiated coverage on Ticketplus Ltd. (AMEX:TP) with a Buy rating and announced a price target of $14. Ticketplus shares closed at $7.83 on Friday. See how other analysts view this stock.
- Stifel analyst James Condulis initiated coverage on Braveheart Bio, Inc. (NASDAQ:BRVE) with a Buy rating and announced a price target of $45. Braveheart Bio closed at $27.44 on Friday. See how other analysts view this stock.
Considering buying LITE stock? Here’s what analysts think:
Photo via Shutterstock